Theranica has published a peer-reviewed study in the Journal of Clinical Medicine confirming that its Nerivio Remote Electrical Neuromodulation (REN) wearable can be safely used alongside common Continuous Glucose Monitoring (CGM) systems without affecting glucose accuracy. The study addresses concerns among patients and providers about potential Bluetooth interference between the migraine treatment device and CGMs such as Abbott FreeStyle Libre and Dexcom.
In the United States, approximately 4.5 million people live with both diabetes and migraines, making multi-device compatibility a critical issue. The study evaluated 21 adults with diabetes who used their CGM devices concurrently with Nerivio during a full 45-minute treatment session. Researchers compared glucose readings during active stimulation versus paused periods to assess measurement accuracy.
Results showed a median glucose deviation of just 1.6%, well below the predefined 5.0% threshold. FreeStyle Libre users demonstrated a median deviation of 1.0%, while Dexcom users showed 1.7%. The study reported no Bluetooth disruptions, missed data transmissions, device malfunctions, or adverse events, confirming functional compatibility and safe simultaneous use.
Researchers noted that migraine management can be more complex for people with diabetes due to metabolic and cardiovascular considerations associated with some medications. Validating safe co-use of wearable technologies helps remove barriers for patients managing both conditions and supports broader adoption of integrated digital health tools.
Click here to read the original news story.